Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ELOVL1 | Q9BW60 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27790040 | 0.85 | CYP2C9 (0.56) | MAPTHTTTSHRHSD17B10L3MBTL1 | |
| SCHEMBL1063920 | 0.85 | CYP2C9 (0.61) | MAPTHTTTSHRHSD17B10L3MBTL1 | |
| SCHEMBL19778587 | 0.82 | KMT2A (0.54) | MAPTHTTTSHRHSD17B10L3MBTL1 | |
| SCHEMBL725497 | 0.81 | CYP2C9 (0.53) | MAPTHTTTSHRHSD17B10L3MBTL1 | |
| SCHEMBL27360401 | 0.81 | CYP2C9 (0.53) | MAPTHTTTSHRHSD17B10L3MBTL1 | |
| SCHEMBL18997594 | 0.81 | ELOVL1 (0.50) | MAPTHTTTSHRHSD17B10L3MBTL1 | |
| SCHEMBL17321495 | 0.81 | ELOVL1 (0.50) | MAPTHTTTSHRHSD17B10L3MBTL1 | |
| SCHEMBL1062877 | 0.81 | ELOVL1 (0.50) | MAPTHTTTSHRHSD17B10L3MBTL1 | |
| SCHEMBL15401858 | 0.81 | MAPT (0.54) | MAPTHTTTSHRHSD17B10L3MBTL1 | |
| SCHEMBL13832650 | 0.81 | GAA (0.66) | MAPTHTTTSHRHSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008092851-A2 | PESTICIDAL COMPOSITIONS COMPRISING 3 -ACETYL-I- PHENYLPYRAZOLE COMPOUNDS | BASF SE (DE) | 2008-08-07 | — | — | WO | claimed |
| EP-3954681-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | Bristol-Myers Squibb Company (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3402790-B1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2021-10-06 | — | — | EP | disclosed |
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-10 | — | — | US | disclosed |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2020-04-30 | — | — | US | disclosed |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-07 | — | — | US | disclosed |
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | BRISTOL MYERS SQUIBB CO (US) | 2019-01-17 | — | — | US | disclosed |
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170247355-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-31 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| US-9556166-B2 | Proteostasis regulators | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20170022221-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-12-10 | — | — | US | disclosed |
| US-20120316193-A1 | PROTEOSTASIS REGULATORS | PROTEOSTASIS THERAPEUTICS, INC. | 2012-12-13 | — | — | US | disclosed |
| WO-2008092851-A3 | PESTICIDAL COMPOSITIONS COMPRISING 3 -ACETYL-I- PHENYLPYRAZOLE COMPOUNDS | BASF SE (DE) | 2009-08-06 | — | — | WO | disclosed |
| WO-2008092851-A2 | PESTICIDAL COMPOSITIONS COMPRISING 3 -ACETYL-I- PHENYLPYRAZOLE COMPOUNDS | BASF SE (DE) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008092851-A2 | PESTICIDAL COMPOSITIONS COMPRISING 3 -ACETYL-I- PHENYLPYRAZOLE COMPOUNDS | BASF SE (DE) | 2008-08-07 | — | — | WO | disclosed |
| JP-2004018487-A | NOXIOUS ORGANISM CONTROLLING AGENT COMPOSITION AND NOXIOUS ORGANISM CONTROLLING METHOD | SUMITOMO CHEM CO LTD | 2004-01-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247355-A1 | PROTEOSTASIS REGULATORS | PSMG3, VCP, HSPA5 | MAPT 577/4885HTT 234/4885TSHR 4284/4885 |
| US-10829501-B2 | Spiroheptane salicylamides and related compounds as inhibitors of ROCK | ROCK1, MYLK, RHOA | MAPT 280/4885HTT 2827/4885TSHR 2955/4885 |
| US-20150353505-A1 | PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS | MYLK, MYLK2, ROCK1 | MAPT 138/4885HTT 2391/4885TSHR 3770/4885 |
| US-20190016735-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | MAPT 291/4885HTT 2939/4885TSHR 2885/4885 |
| US-10611776-B2 | Spiroheptane salicylamides and related compounds as inhibitors of rock | ROCK1, MYLK, RHOA | MAPT 291/4885HTT 2939/4885TSHR 2885/4885 |
| US-20120316193-A1 | PROTEOSTASIS REGULATORS | PSMG3, VCP, HSPA5 | MAPT 577/4885HTT 234/4885TSHR 4284/4885 |
| US-20170022221-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | MAPT 2157/4885HTT 4383/4885TSHR 1396/4885 |
| US-20160016914-A1 | SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK | ROCK1, MYLK, ROCK2 | MAPT 171/4885HTT 3108/4885TSHR 1625/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | MAPT 2731/4885HTT 4394/4885TSHR 4461/4885 |
| US-20200131200-A1 | SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK | ROCK1, MYLK, RHOA | MAPT 280/4885HTT 2827/4885TSHR 2955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.